ReviewBDJ open2026
Adipokines in oral squamous cell carcinoma-a narrative overview.
Review in BDJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify and summarize the types of adipokines associated with Oral Squamous Cell Carcinoma (OSCC) pathogenesis and prognosis. MATERIALS AND
methodsA comprehensive literature search was done involving Scopus, PubMed, and Embase. Studies involving adipokines in OSCC conducted in humans were included.
resultsAdipokines have diverse and stage-dependent effects on OSCC, including regulation of inflammation, angiogenesis, hypoxia, and tumour progression. Adipokines such as chemerin, resistin, leptin, and apelin contribute to tumour progression. Zinc alpha-2-glycoprotein and adiponectin were found to be antitumourigenic in OSCC. Methodological heterogeneity and a lack of standardized outcome measures limit comparability across studies to establish the definitive role of adipokines in OSCC.
conclusionAdipokines shape OSCC biology through diverse, stage-specific mechanisms, making them potential biomarkers of disease progression. The adipokines reported in OSCC require validation through long-term prospective studies and addressing methodological heterogeneity to serve as prognostic markers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.